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Embryonic stem cells can provide an unlimited supply of pluripo-
tent cells for tissue engineering applications. Bone tissue engineer-
ing by directly differentiating ES cells (ESCs) into osteoblasts has
been unsuccessful so far. Therefore, we investigated an alternative
approach, based on the process of endochondral ossification. A
cartilage matrix was formed in vitro by mouse ESCs seeded on a
scaffold. When these cartilage tissue-engineered constructs
(CTECs) were implanted s.c., the cartilage matured, became hyper-
trophic, calcified, and was ultimately replaced by bone tissue in the
course of 21 days. Bone aligning hypertrophic cartilage was ob-
served frequently. Using various chondrogenic differentiation pe-
riods in vitro, we demonstrated that a cartilage matrix is required
for bone formation by ESCs. Chondrogenic differentiation of mes-
enchymal stem cells and articular chondrocytes showed that a
cartilage matrix alone was not sufficient to drive endochondral
bone formation. Moreover, when CTECs were implanted ortho-
topically into critical-size cranial defects in rats, efficient bone
formation was observed. We report previously undescribed ESC-
based bone tissue engineering under controlled reproducible con-
ditions. Furthermore, our data indicate that ESCs can also be used
as a model system to study endochondral bone formation.
osteoblast  cartilage  endochondral ossification  scaffold  in vivo
Bone tissue engineering is generally approached by combiningosteogenic cells with a porous biodegradable ceramic scaf-
fold. Human bone marrow-derived mesenchymal stem cells
(MSCs) can be differentiated into the osteogenic lineage by
culturing the cells in the presence of the osteogenic differenti-
ation supplements dexamethasone, ascorbic acid, and -glycero-
phosphate (1, 2). Mineralized bone matrix is deposited in vitro as
a result of the expression of osteogenic genes (3), and de novo
bone formation is observed when human MSCs are implanted
into an ectopic or orthotopic site (2). Even though MSCs from
most human donors show osteogenic potential, there is large
variation in bone-forming capacity by human MSCs, and mul-
tipotency is gradually lost upon expansion (4). Most importantly,
bone formation by MSCs is currently insufficient for successful
tissue engineering (5). Besides efforts to increase bone forma-
tion by MSCs in vivo, we also explore ES cells (ESCs) (6–8) as
a potential source for bone tissue engineering. ESCs are capable
of indefinite undifferentiated proliferation in vitro and can
provide an unlimited supply of cells, which can be differentiated
into various cell types (9).
Before ESCs can be used in clinical applications, some tech-
nical issues have to be addressed, such as the labor-intensive
procedure and the use of animal-derived reagents to expand
human ESCs, the immunogenicity of allogeneic ESCs and the
potential risk of tumorigenicity. Moreover, a differentiation
scheme has to be designed to obtain the desired cell or tissue
type. Osteogenic differentiation of mouse and human ESCs has
been established in vitro by culturing the cells in medium
supplemented with ascorbic acid, -glycerophosphate, dexa-
methasone (10–12), BMP2 (13), compactin (13), or vitamin D3
(14). Mineralization was observed, and qPCR analysis showed
up-regulation of osteogenic markers such as Cbfa-1/Runx2,
osteopontin, bone sialoprotein, and osteocalcin. We observed
similar results when mouse and human ESCs were differentiated
into the osteogenic lineage in vitro (unpublished work). To assess
bone tissue engineering using ESCs, we seeded human or mouse
ESCs onto ceramic scaffolds and cultured them in osteogenic
media for 7 or 21 days. Six weeks after implantation into
immunodeficient mice, no bone tissue was observed in samples
of mouse ESCs (unpublished work). For human ESCs, we
observed some in vivo mineralized tissue, but no bone tissue, as
reported (11). So far, in vivo bone formation by ESCs has been
observed only in teratomas. Strikingly, it occurred to us that
bone tissue in teratomas frequently aligns hypertrophic cartilage,
which resembles the process of endochondral ossification. Most
bones in the body are formed via endochondral ossification,
which involves the formation of cartilage tissue from condensed
mesenchymal cells and the subsequent replacement of the
cartilage template by bone. In contrast, direct conversion of
mesenchymal tissue into bone is called intramembranous ossi-
fication, which occurs primarily in the craniofacial skeleton.
Here, we describe an alternative approach to in vivo bone
formation using ESCs, based on the process of endochondral
ossification.
Results
Chondrogenic Differentiation of Mouse ESCs in Vitro and Bone For-
mation in Vivo. It is well established that osteogenic human MSC
mineralize in vitro (Fig. 1A) and form bone in vivo (Fig. 1B) (2).
This process of ossification occurs through intramembranous
ossification, without the intermediate production of cartilage
(data not shown). Moreover, it is known that mouse ESCs, like
MSCs, can be induced into the osteogenic lineage in vitro as
indicated by mineralization (Fig. 1C) and the up-regulation of
osteogenic genes. However, in contrast to human MSCs, these
osteogenic mouse ESCs did not form bone upon implantation
(Fig. 1D). Therefore, we assessed an alternative approach:
endochondral ossification, in which ESCs first deposit cartilage,
which may serve as a template for ossification. In previous
studies, we have shown cartilage formation by mouse ESCs in
pellets, on polymeric scaffolds, and in hydrogels (15). We now
assessed the chondrogenic potential of mouse ESCs on ceramic
scaffolds. ESC-derived embryoid body (EB) cells were seeded on
ceramic particles and cultured in serum-free chondrogenic dif-
ferentiation medium containing TGF3 for 21 days. Regions
with typical cartilage morphology, that is round cells with
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lacunae surrounded by extracellular matrix, were found on the
outside of the particles and inside the pores (Fig. 1E). Cartilage
was formed in each sample cultured in chondrogenic medium
and approximately one-tenth to one-third of the cells on the
particles differentiated into chondrocytes. Collagen type II
expression was substantially up-regulated compared to control
cultures (data not shown). Particles cultured in control or
osteogenic medium did not show formation of cartilage (data not
shown).
After creating a cartilage template on ceramic particles by
differentiating mouse ESCs into the chondrogenic lineage for 21
days in vitro [hereafter referred to as cartilage tissue-engineered
constructs (CTECs)], the next step was to demonstrate in vivo
bone formation. Therefore, CTECs were implanted s.c. in the
back of immunodeficient mice for 21 days. Bone-like tissue was
formed in all samples, which were differentiated into the chon-
drogenic lineage (Fig. 1F), in contrast to the samples, which were
differentiated into the osteogenic lineage in vitro (Fig. 1D), in
which bone tissue was never observed. The newly formed bone,
also known as osteoid, was aligned with osteoblasts, which were
visible in themature andmineralized bone tissue (Fig. 1G). Bone
was formed both on the outside of the particles, as within the
pores, and the tissue consisted of lamellar bone as demonstrated
by polarized light (Fig. 1H). We demonstrate directed, repro-
ducible bone formation using mouse ESCs in vivo.
A Time Course of Endochondral Bone Formation by Mouse ESCs.Next,
we investigated the fate of in vitro formed cartilage after
implantation and the process of bone formation in vivo. There-
fore, we analyzed the CTECs 2, 7, 14, or 21 days after implan-
tation (Fig. 2A). At the time of implantation, cartilage tissue was
present on the CTECs, and hardly any cellular stroma was
observed. After 2 days in vivo, cartilaginous tissue was still
present on the implanted CTECs, indicating the survival of the
implanted tissue. The CTECs showed different amounts of
fibrous immature scar-like tissue that showed a resemblance to
mesenchymal cells in tissue cultures. After 7 days in vivo, the
cartilage showed the beginning of maturation indicated by larger
lacunae with smaller uniform nuclei. The onset of endochondral
calcification was indicated by slight basic fuchsin staining within
the mature cartilage. Furthermore, the fibrous stroma became
more cellular and dense and contained more vessels. Bone
formation was first seen after 14 days in vivo. Bone surrounded
hypertrophic chondrocytes and the mineralized cartilage matrix
(Fig. 2B). In some regions, cartilage seemed to be totally
replaced by bone, and in other regions, mature cartilage was still
present. After 21 days in vivo, hardly any cartilage remained, and
more bone tissue was observed than after 14 days. We even
observed tissue resembling bone marrow in some bone lacunae
(Fig. 2A).
The gradual decrease in the amount of cartilage and a gradual
increase in the amount of bone tissue in time were confirmed by
histomorphometric analysis. After 21 days, there was signifi-
cantly less cartilage and significantly more bone per scaffold area
than at earlier time points. There was also significantly more
bone than cartilage after 21 days (Fig. 2C). Thus, in the course
of 21 days in vivo, almost all cartilage matured and was replaced
by bone tissue.
A Cartilage Template from ESCs Is Necessary for Endochondral Bone
Formation. We investigated whether either chondrogenic stimu-
lation or cartilaginous tissue was required for in vivo bone
formation. Therefore, we differentiated cells in vitro for 3, 7, 14,
and 21 days and subsequently implanted these samples for
another 21 days into immunodeficient mice. In vitro chondro-
genic differentiation for 3 and 7 days did not result in tissue with
typical cartilage morphology. After 14 days, the first, mainly
small, cartilaginous regions were observed, and more and larger
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Fig. 1. Two approaches for in vivo bone formation by MSCs and ESCs. (A)
In vitro osteogenic differentiation of human MSCs cultured on tissue
culture plastic for 21 days, indicated by von Kossa staining, which stains
mineralized matrix black. (B) In vivo, bone is formed by human MSCs, as
shown by the methylene blue and basic fuchsin stained sections of cells
grown on ceramic particles for 7 days and implanted s.c. into immunode-
ficient mice for 6 weeks. Bone tissue stains pink, and bone-lining cells are
indicated by a black arrowhead. (C) In vitro osteogenic differentiation of
mouse ESCs cultured on tissue culture plastic for 21 days, indicated by black
von Kossa staining of the mineralized matrix. (D) After 21 days, no bone is
formed in vivo by mouse ESCs, which were precultured in vitro for 21 days
on ceramic particles in osteogenic medium. (E) In the process of endochon-
dral ossification, bone is formed on a cartilage template. Mouse ESCs were
cultured in chondrogenic medium on ceramic particles for 21 days. Cells
displayed a chondrocyte phenotype, as indicated by round cells in lacunae
surrounded by extracellular matrix, which stained positive for glycosami-
noglycans (indicated by pink thionin staining). (F) CTECs were implanted
s.c. for another 21 days to demonstrate bone formation. Bone tissue is
stained dark pink by basic fuchsin. (G) Higher magnification of bone tissue
observed on implanted CTECs. Bone-lining cells are indicated by a black
arrowhead and osteocytes by an open arrowhead. (H) The bone tissue that
was formed consisted of lamellar bone, as indicated by polarized light. sc,
ceramic scaffolds; b, bone; c, cartilage. (Scale bar, 100 m.)
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regions of cartilage tissue were formed after 21 days of in vitro
culture (Fig. 3A). After 14 days in vitro, we scored 0–5 cartilage
nodules, with an average of 2.4 (12 sections), and for the 21-day
CTECs, we observed 11–34 nodules, with an average of 21.7
nodules/section (Fig. 3C). After subsequent implantation for 21
days, we scored the amount of bone nodules aligning the ceramic
particle in all histological sections (five to seven sections per
sample, six mice per time point). No bone nodules were observed
in the 3-day samples. For the samples that had been differenti-
ated in vitro for 7 days, we observed one bone nodule in a few
sections, with an average of 0.2 bone nodules per section. For the
14-day CTECs, we observed 0–13 bone nodules in the sections
with an average of 4.6, and for the 21-day CTECs, we observed
2–20 bone nodules with an average of 9.2 bone nodules/section
(Fig. 3C). Thus, bone was mainly observed in the samples that
had been differentiated into the chondrogenic lineage for 14
days and 21 days (Fig. 3B). In consistency with the higher amount
of cartilage in vitro, the highest amount of bone was found in the
21 days samples. We conclude that a cartilage template is
required for bone formation.
A Cartilage Template Is Not Sufficient for Endochondral Bone Forma-
tion. To investigate whether any cartilage template will mature,
calcify and will be replaced by bone, we implanted cartilage
derived from articular chondrocytes and adult stem cells.
Freshly isolated calf chondrocytes were cultured on ceramic
particles in chondrocyte proliferation medium. After 21 days in
vitro, cartilage and some fibrous tissue was formed on the
ceramic particles (Fig. 4A). Subsequently, these constructs were
implanted into immunodeficient mice. The cartilage phenotype
was stable in vivo and more cartilage matrix was deposited (Fig.
4B). Hypertrophy and calcification of the cartilage matrix was
not observed. No signs of endochondral ossification were ob-
served when articular chondrocyte-derived cartilage was
implanted.
We also investigated the fate of a cartilage template derived
from adult stem cells. Given that even nonstimulated MSCs can
form bone in vivo, we had to look for signs of endochondral
ossification other than sheer bone formation, such as hypertro-
phic chondrocytes, calcified matrix, and regions where bone
aligns and replaces cartilage. We seeded goat and human MSCs
on ceramic particles and differentiated these cells into the
chondrogenic lineage as described for ESCs. Cartilaginous tissue
was formed by goat MSCs, which was almost homogeneous in
some samples (Fig. 4A). Human MSCs proliferated on the
ceramic particles, and a small amount of GAG-positive tissue
was observed (Fig. 4A), limited to one to three small regions per
sample.
Next, these CTECs were implanted into immunodeficient
mice for an additional 21 days. Cartilaginous tissue was still
observed, and bone was formed in vivo (Fig. 4B).
Bone formation in human MSC samples remained limited to
an average of 2.6 small bone nodules per sample, similar to the
rather inefficient chondrogenic differentiation in vitro. No signs
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Fig. 2. In vivo bone formation throughout time. (A) Representative images of histological sections of CTECs 0, 2, 7, 14, and 21 days after implantation. At 0
and 2 days in vivo, cartilage matrix is visualized by pink thionin staining of glycosaminoglycans. At 7, 14, and 21 days in vivo, bone tissue is stained by methylene
blue and basic fuchsin staining, which stains cells blue and bone tissue dark pink. Cartilage can still be recognized by morphology, that is extracellular matrix
in which single cells in a lacuna can be distinguished. (B) Higher-magnification image of a CTEC after 14 days in vivo, showing the process of endochondral
ossification. Hypertrophic chondrocytes in mineralized cartilage were surrounded by bone tissue. (Scale bars, 100 m.) (C) Histomorphometric analysis of the
amount of cartilage and bone per available scaffold area in time.
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of endochondral ossification were observed in these few bone
nodules.
Extensive bone formation was observed in the implanted goat
MSC CTECs, up to 40 bone nodules per section. Most bone
appeared to be formed by the process of intramembranous
ossification, as also observed when nonstimulated cells were
implanted. However, in 14% of the bone regions, bone-aligned
cartilage or calcified areas were observed in the cartilaginous
tissue. Even though we did not observe the typical replacement
of hypertrophic cartilage by bone, as observed with mouse ESCs
(Fig. 2B), these areas are indications of the onset of endochon-
dral bone formation by goat MSCs. In studies with mouse ESCs,
hardly any cartilage was observed after 21 days in vivo (Fig. 2C).
However, large regions of cartilage were still present in the
implanted goat MSCs samples (Fig. 4B). Of the implanted large
cartilaginous regions,80% did not show signs of endochondral
ossification after implantation.
Based on these experiments, we conclude that a cartilaginous
matrix does not automatically lead to endochondral bone for-
mation, but rather that stem-cell- and especially ESC-derived
cartilage has a tendency to mature and enter the process of
endochondral ossification.
Bone Tissue Engineering in an Orthotopic Defect. The above-
mentioned in vivo studies were restricted to ectopic implan-
tation sites. To study bone formation in an orthotopic defect,
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Fig. 3. The necessity of a cartilage template for in vivo bone formation using
mouse ESCs. (A) Chondrogenic differentiation of mouse ESCs for 3, 7, 14, and
21 days in vitro, as indicated by thionin staining. Cartilage matrix was first
observed after 14 days of chondrogenic differentiation and the amount
increased in time as seen after 21 days. (B) Subsequent implantation for 21
days after in vitro differentiation for 3, 7, 14, and 21 days. Bone tissue was
observed in the 14 21 and 21 21 days samples, as indicated by basic fuchsin
staining. (Scale bars, 100m.) (C) Average amount of cartilage nodules in vitro
and bone nodules in vivo in time, scored per section.
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Fig. 4. A cartilage template is not sufficient to induce endochondral bone
formation. (A) In vitro cartilage formation by bovine chondrocytes, goat MSCs,
and human MSCS, stained by thionin. (B) Subsequent implantation of the in
vitro samples as displayed in A. No bone was formed in the bovine cartilage
samples. Bone was observed in both goat MSCs and human MSC samples, as
indicated by basic fuchsin staining. (Inset) In some regions, bone aligned
cartilage. Cartilaginous tissue (c) was still present in goat MSC samples. (Scale
bars, 100 m.)
Jukes et al. PNAS  May 13, 2008  vol. 105  no. 19  6843
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
we implanted CTECs or empty scaffolds in an 8-mm critical-
size cranial defect in an immunodeficient rat. After 21 days,
cartilage was observed in all in vitro discs (CTECs; data not
shown).
The cranial defect proved critical, because bone in-growth did
not bridge the sham implant. To distinguish between bone
in-growth from the cranium and bone formation using ESCs, all
samples were divided in an outer ring, containing the regions of
bone in-growth, and an inner ring, in which bone in-growth was
not observed in the sham implants (Fig. 5A). The percentage of
bone in the inner circle of sham implants and CTECs (Fig. 5C)
was determined by histomorphometry (Fig. 5B). Significantly
more bone was observed in the inner circle of CTECs, as
compared with sham implants. Hereby, we show efficient bone
formation using ESCs in an orthotopic defect.
Discussion
In this article, we describe in vivo bone formation using mouse
ESCs. We first attempted to directly differentiate ESCs into the
osteogenic lineage, based on differentiation protocols andmedia
established for adult stem cells (3) and osteoblasts. Although in
vitro results were satisfying, in vivo experiments did not result in
bone formation, by either mouse or human ESCs. We opted for
an alternative approach by first forming a cartilage template and
subsequently allowing the cartilage to be replaced by bone. Using
this approach, we demonstrated previously undescribed directed
and reproducible in vivo bone formation using ESCs in ectopic
and orthotopic sites. The process is very robust, because we
observed bone in all experiments where an ESC-derived carti-
lage template was formed in vitro. The amount of bone formed
in these experiments was comparable to the amounts formed by
rat and goat MSCs (data not shown). We also observed endo-
chondral bone formation on polymeric scaffolds, indicating that
in vivo bone formation was not induced by and is not exclusive
to ceramic scaffolds (data not shown).
Most, if not all, differentiation protocols result in a hetero-
geneous population of ESCs differentiated into various lineages
but enriched for the desired cell type. Cartilage and bone were
formed in all experiments, but ESCs also differentiated into
other less or more advanced tissue types, like squamous and
cylindrical epithelial cells lining cyst-like spaces and tubules,
endothelial cells lining (blood) vessels, fat, and stroma. In some
experiments, we even observed teratoma formation. Cartilage,
hypertrophic and calcified cartilage, and some bone were ob-
served in the teratomas, but in contrast to our directed differ-
entiation, these tissues did not align the scaffold material. For
future application, the constructs should be purified from re-
sidual undifferentiated ESCs to avoid teratoma formation in
vivo. In addition, purification could result in more homogeneous
cartilage formation, which might result in improved bone
formation.
Currently, we are investigating which cell population is
responsible for bone deposition. A subpopulation of mesoder-
mal or osteoprogenitor cells might be present in the implanted
heterogeneous ESC population, which differentiate into os-
teoblasts and deposit bone matrix. Alternatively, as during
bone growth, blood vessels infiltrate the cartilage matrix, and
host cells might form bone tissue stimulated by factors secreted
by the hypertrophic chondrocytes. Blood vessels close to the
cartilage matrix were observed frequently in the samples.
The next step will be to show in vivo bone formation using
human ESCs. When human ESCs were differentiated into the
osteogenic lineage, small fragments of mineralized tissue were
observed in vivo (11), but no osteocytes and osteoblasts were
observed. The first step in endochondral bone formation by
human ESCs would be the formation of a cartilage template. The
chondrogenic potential of human ESCs has been demonstrated
in indirect coculture experiments with primary chondrocytes
(16). Whereas mouse ESCs show consistent cartilage formation,
we did not observe cartilage formation when the chondrogenic
protocols were transferred to human ESCs (data not shown).
Not only did the serum-free chondrogenic medium containing
TGF3 result in heterogeneous cartilage formation by mouse
ESCs, but also the cartilaginous tissue that was formed by human
MSCs in our studies was not homogeneous (data not shown),
even when supplemented with BMP6. Further optimization of
the growth-factor regime for both adult and ESCs is necessary
(17, 18).
Mouse ESC-derived cartilage displayed maturation, calcifi-
cation, and subsequent replacement by bone tissue. Indications
of maturation were also observed for human ESC-derived
cartilaginous tissue (16, 18) Apparently, ESCs followed the
route of embryonic development. This implicates that ESCs
can be used as a model system to study endochondral bone
formation. Where most current models use chicken eggs, in
vitro limb cultures, or transgenic mice, our results show that
endochondral bone formation can now be studied with ESCs.
Transgenic ESCs, rather than transgenic mice, can be used to
investigate the inf luence of several genes in the process of
endochondral bone formation. Besides in vitro assays, in vivo
bone formation can be studied in ectopic and orthotopic
models. The orthotopic defect used in our studies might not be
the most logical model for endochondral bone formation,
because it is well known that the bones of the craniofacium
form through intramembranous ossification. However, this
study does demonstrate that the implanted mouse ESCs result
in bone formation in an orthotopic defect in a rat.
In conclusion, our data show that mouse ESCs readily undergo
endochondral ossification after deposition of a cartilage matrix,
which can benefit both bone tissue engineering and the genetic
dissemination of endochondral bone formation.
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Fig. 5. Orthotopic bone formation using ESCs in a rat cranial defect. (A) Bone
formation in an 8-mm CTEC implanted for 21 days in a critical-size cranial
defect in a rat, visualized by methylene blue and basic fuchsin staining. For
subsequent analysis, the sample was divided in an outer and inner ring,
indicated by yellow circles. (B) Histomorphometric analysis of bone tissue
formed in the inner circle of sham implants and CTECs. (C) Higher-
magnification view of the inner circle (2.7 mm) of a sham implant and a CTEC.
sc, scaffold. (Scale bar, 500 m.)
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Materials and Methods
Cell Culture. Mouse ESC line IB10 was cultured, and embryoid bodies were
formed as described in ref. 15. ESC-derived embryoid body cells were used for
differentiation experiments. Human MSCs were isolated from bone marrow
aspirates from donors who had given written informed consent (2). Goat MSCs
and calf articular chondrocytes were isolated as described (19, 20).
Differentiation. Aliquots of 1.5 million cells were seeded onto three ceramic
particles of 2–3 mm, prepared as described by Yuan et al. (21). For cranial
implants, one million cells were seeded statically on both sides of the 8 
1.5-mm disk. Further differentiation of stem cells into the chondrogenic
lineage was performed in serum-free chondrogenic medium containing
TGF3 (22). For differentiation of human MSCs, the chondrogenic medium
was supplemented with 250 ng/ml human BMP6 (Biovision) (23). For differ-
entiation into the osteogenic lineage, EB cells were cultured for another 3 days
in medium supplemented with 107 M retinoic acid (Sigma) and subsequently
in medium supplemented with 0.2 mM ascorbic acid, 2.5 M compactin
(Sigma) and 0.01 M -glycerophosphate (Sigma) (adapted from ref. 13).
Osteogenic differentiation of human MSC was described by Both et al. (2).
In Vivo Studies. Samples were precultured in chondrogenic or osteogenic
medium for 21 days and subsequently implanted into immunodeficient mice
(HsdCpb:NMRI-nu Harlan, n 6) for 21 days, unless indicated otherwise (15).
For cranial implantation, immunodeficient rats (Crl:NIH-Foxnrnu; Charles
River) were injected s.c. with 0.02 mg/kg buprenorphine (Temgesic) for pain
relief. The rats were induced with 4–5% isoflurane, and during the operation,
they were maintained with a mixture of isoflurane (1.5–3%), O2 (200–300
ml/min) and N2O (50–200 ml/min). An incision was made in the skin over the
cranium from the middle of the nasal bones to the posterior nuchal line. The
periostium was sedated with Lidocaine (2%) and removed. An 8-mm trephine
dental bur (ACEuropa, Lda) was used to mark the defect site and a 0.7-mm drill
(Synthes) was used to remove the bone to realize the craniotomy. An implant
was press-fitted into the defect site. Six rats received a sham implant, and
seven rats received a CTEC. The overlaying tissue was sutured back in layers.
After 4 weeks, implants were removed and processed histologically as de-
scribed below. Animals were housed at the Central Laboratory Animal Insti-
tute (Utrecht University, Utrecht, The Netherlands), and experiments were
approved by the local animal care and use committee.
Histological Staining and Light Microscopic Analysis. Samples were fixed in
0.25% glutaraldehyde (Merck) in 0.14 M cacodylate buffer and dehydrated
using sequential ethanol series. Scaffolds were embedded in methyl methac-
rylate (LTI), and sections were processed on a histological diamond saw (Leica
SP1600). Sections were etched with an HCl/ethanol mixture and sequentially
stained to visualize cartilage and bone. Cartilage formation was visualized by
0.04% thionin (Sigma) in 0.1 M sodium acetate (Merck), which stained cells
blue and glycosaminoglycans pink. Bone formation was visualized by 1%
methylene blue (Sigma) and 0.03% basic fuchsin (Sigma), which stained cells
blue and bone pink. Histological sections were analyzed by using a light
microscope (E600 Nikon). For mineralization studies, ESC-derived EBs or MSCs
were grown on tissue culture plates in osteogenic medium for 21 days, fixed
and incubated with 5% silver nitrate (Sigma) under a UV lamp, until black
staining was observed.
Histomorphometry. Histomorphometry was performed on particles that were
explanted at different time points and on the inner circle of cranial implants.
Low-magnification images were made from two to three sections per sample.
Scaffold, bone, and cartilage were pseudocolored, and image analysis was
performed with KS400 software (Zeiss Vision). A custom-made program (Uni-
versity of Utrecht) was used to measure percentage of cartilage or bone
compared to scaffold area.
Statistical Analysis. Statistical calculations were performed with SPSS 14.0
software. Histomorphometric data for particles were not normally distrib-
uted. Therefore, we used nonparametric tests to compare the amount of
cartilage and bone in time (Kruskal–Wallis) and the amount of cartilage and
bone at different time points (Wilcoxon signed-rank test). For the cranial
implants, the samples of the sham group showed little to no bone in-growth
in the inner circle, whereas bone was formed in all tissue-engineered samples.
Because of the lack of variation in the sham group, we calculated the mean of
the three images for each sample and a Mann–Whitney U test was used to
detect a difference between the two groups.
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